Ionis Pharmaceuticals Inc [IONS] stock prices are up 1.78% to $64.09 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IONS shares have gain 5.05% over the last week, with a monthly amount glided 49.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on September 26, 2025, when Goldman upgraded its rating to a Neutral but kept the price target unchanged to $65 for it. Previously, BMO Capital Markets upgraded its rating to Outperform on September 03, 2025, and kept the price target unchanged to $70. On July 31, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $62 on the stock. Barclays upgraded its rating to a Overweight but stick to its price target of $57 on July 01, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $45 as its price target on April 07, 2025. Redburn Atlantic started tracking with a Neutral rating for this stock on March 31, 2025, and assigned it a price target of $39. In a note dated August 02, 2024, BMO Capital Markets downgraded an Market Perform rating on this stock and revised its target price from $67 to $60.
The stock price of Ionis Pharmaceuticals Inc [IONS] has been fluctuating between $23.95 and $64.71 over the past year. Currently, Wall Street analysts expect the stock to reach $75.9 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $64.09 at the most recent close of the market. An investor can expect a potential return of 18.43% based on the average IONS price forecast.
Analyzing the IONS fundamentals
The Ionis Pharmaceuticals Inc [NASDAQ:IONS] reported sales of 944.48M for trailing twelve months, representing a surge of 100.69%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.45 and Total Capital is -0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.26 points at the first support level, and at 62.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 64.70, and for the 2nd resistance point, it is at 65.32.
Ratios To Look Out For
It’s worth pointing out that Ionis Pharmaceuticals Inc [NASDAQ:IONS]’s Current Ratio is 2.87. Further, the Quick Ratio stands at 2.86, while the Cash Ratio is 0.33. Considering the valuation of this stock, the price to sales ratio is 10.82, the price to book ratio is 16.15.
Transactions by insiders
Recent insider trading involved O’NEIL PATRICK R., EVP CLO & General Counsel, that happened on Sep 12 ’25 when 1700.0 shares were sold. EVP, Chief Business Officer, Baroldi Joseph completed a deal on Sep 09 ’25 to sell 11950.0 shares. Meanwhile, EVP CLO & General Counsel O’NEIL PATRICK R. sold 21000.0 shares on Sep 09 ’25.
